Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

Autor: Morieri, M. L., Raz, I., Consoli, A., Rigato, M., Lapolla, A., Broglio, F., Bonora, E., Avogaro, A., Fadini, G. P., Ginestra, F., Formoso, G., Andreozzi, F., Sesti, G., Turco, S., Lucibelli, L., Gatti, A., Aldigeri, R., Dei Cas, A., Felace, G., Li Volsi, P., Sorice, G. P., Giaccari, A., Mignogna, C., Buzzetti, R., Filardi, T., Morano, S., Barchetta, I., Gisella Cavallo, M., Malandrucco, I., Frontoni, S., Carletti, S., D'Angelo, P., Leto, G., Leonetti, F., Silvia Morpurgo, P., Fiorina, P., Palmieri, E., Orsi, E., Mantovani, E., Franzetti, I., Querci, F., Bossi, A., Turchi, F., Manfrini, S., Guida, D., Placentino, G., Beccuti, G., Cavalot, F., Nuzzo, A., Aimaretti, G., Lamacchia, O., Cignarelli, A., Laviola, L., Giorgino, F., Devangelio, E., Cazzetta, G., Chianetta, R., Citarrella, R., Tumminia, A., Frittitta, L., Anzaldi, M., Buscema, M., Piro, S., Di Pino, A., Purrello, F., Di Benedetto, A., Russo, G., Anichini, R., Solini, A., Garofolo, M., Del Prato, S., Fattor, B., Paolo Fadini, G., Sartore, G., D'Ambrosio, M., Da Tos, V., Frison, V., Simioni, N., Cigolini, M., Brun, E., Strazzabosco, M., Poli, M., Paccagnella, A., Vinci, C.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::eff62cbbb0367fcc1110aad7a2df0f90
https://hdl.handle.net/2318/1885726

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study

Autor: Fadini, G. P., Sciannameo, V., Franzetti, I., Bottigliengo, D., D'Angelo, P., Vinci, C., Berchialla, P., Arena, S., Buzzetti, R., Avogaro, A., Consoli, A., Formoso, G., Grossi, G., Pucci, A., Sesti, G., Andreozzi, F., Capobianco, G., Gatti, A., Bonadonna, R., Zavaroni, I., Cas, A. D., Felace, G., Volsi, P. L., Leto, G., Sorice, G. P., Morano, S., Bossi, A. C., Duratorre, E., Morpurgo, P. S., Orsi, E., Querci, F., Boemi, M., D'Angelo, F., Petrelli, M., Aimaretti, G., Karamouzis, I., Cavalot, F., Saglietti, G., Cazzetta, G., Cervone, S., Devangelio, E., Lamacchia, O., Di Benedetto, A., Frittitta, L., Giordano, C., Piro, S., Rizzo, M., Chianetta, R., Mannina, C., Anichini, R., Penno, G., Solini, A., Fattor, B., Bonora, E., Cigolini, M., Lapolla, A., Chilelli, N. C., Poli, M., Simioni, N., Frison, V.

Publikováno v: Diabetes, Obesity & Metabolism

Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ce227387e054af04ea1aad47238be7
http://hdl.handle.net/11577/3302856

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study

Autor: Fadini, Gian Paolo, Bottigliengo, Daniele, D'Angelo, Federica, Cavalot, Franco, Bossi, Antonio Carlo, Zatti, Giancarlo, Baldi, Ileana, Avogaro, A, Consoli, A, Formoso, G, Grossi, G, Pucci, A, Sesti, G, Andreozzi, F, Capobianco, G, Gatti, A, Bonadonna, R, Zavaroni, I, Cas, Ad, Felace, G, Volsi, Pl, Buzzetti, R, Leto, G, Sorice, Gp, D'Angelo, P, Morano, S, Bossi, Ac, Duratorre, E, Franzetti, I, Morpurgo, Ps, Orsi, E, Querci, F, Boemi, M, D'Angelo, F, Petrelli, M, Aimaretti, G, Karamouzis, I, Cavalot, F, Saglietti, G, Cazzetta, G, Cervone, S, Devangelio, E, Lamacchia, O, Arena, S, Benedetto, Di, A, Frittitta, L, Giordano, C, Piro, S, Rizzo, M, Chianetta, R, Mannina, C, Anichini, R, Penno, G, Solini, A, Fattor, B, Bonora, E, Cigolini, M, Lapolla, A, Chilelli, Nc, Poli, M, Simioni, N, Frison, V, Vinci, C

Publikováno v: Diabetes Therapy

Introduction DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods This was a multicent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf78f9c28b3a572d3a1d52646fe4120
http://hdl.handle.net/11577/3287224

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity

Autor: Fadini, G. P., Zatti, G., Consoli, A., Bonora, E., Sesti, G., Avogaro, Consoli A, A. DARWIN-T2D. Network., Formoso, G, Antenucci, D, Grossi, G, Pucci, A, Sesti, G, Andreozzi, F, Indrieri, L, Capobianco, G, Gatti, A, Bonadonna, R, Zavaroni, I, Dei Cas, A, Felace, G, Li Volsi, P, Buzzetti, R, Leto, G, D'Angelo, F, Morano, S, Giaccari, A, Sorice, G, Orsi, E, Carlo Bossi, A, Querci, F, Duratorre, E, Malagola, C, Franzetti, I, Silvia Morpurgo, P, Boemi, M, Petrelli, M, Aimaretti, G, Karamouzis, I, Cavalot, F, Saglietti, G, Gruden, G, Devangelio, E, Cazzetta, G, Lamacchia, O, Cervone, S, Frittitta, L, Arena, S, Di Benedetto, A, Piro, S, Giordano, C, Rizzo, M, Chianetta, R, Mannina, C, Solini, A, Natali, A, Anichini, R, Dotta, F, Fattor, B, Avogaro, A, Fadini, Gp, Bonora, E, Cigolini, M, Simioni, N, Frison, V, Poli, M, Lapolla, A, Cristiano Chilelli, N, Author information, Vinci C.

Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f7aa263ca27b8ac0678785ddb9d534ad
http://hdl.handle.net/10447/414947